Encompass Health (NYSE:EHC) Raised to “Buy” at Wall Street Zen

Encompass Health (NYSE:EHC) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday, Wall Street Zen reports.

Other research analysts have also issued research reports about the company. Truist Financial increased their target price on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Barclays upped their price target on Encompass Health from $140.00 to $144.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. UBS Group increased their price objective on Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a report on Friday, August 7th. TD Cowen raised their price objective on Encompass Health from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, Weiss Ratings upgraded shares of Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $148.20.

Encompass Health Trading Up 0.0%

NYSE:EHC opened at $123.53 on Friday. The company has a 50-day moving average price of $119.62 and a 200-day moving average price of $109.11. The stock has a market cap of $12.19 billion, a price-to-earnings ratio of 20.12, a P/E/G ratio of 2.50 and a beta of 0.75. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health has a 12 month low of $92.77 and a 12 month high of $127.99.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. Encompass Health’s revenue was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Equities analysts predict that Encompass Health will post 6.08 EPS for the current year.

Insider Activity at Encompass Health

In related news, CEO Mark Tarr sold 173,148 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the completion of the transaction, the chief executive officer owned 267,814 shares of the company’s stock, valued at $33,602,622.58. This trade represents a 39.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John Darby sold 4,858 shares of Encompass Health stock in a transaction on Monday, August 31st. The shares were sold at an average price of $121.09, for a total value of $588,255.22. Following the transaction, the executive vice president owned 75,041 shares of the company’s stock, valued at $9,086,714.69. The trade was a 6.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 186,912 shares of company stock worth $23,434,845 in the last 90 days. 1.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Encompass Health

Large investors have recently modified their holdings of the stock. QRG Capital Management Inc. boosted its stake in Encompass Health by 9.0% in the 2nd quarter. QRG Capital Management Inc. now owns 9,414 shares of the company’s stock worth $952,000 after purchasing an additional 775 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Encompass Health by 2.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,571 shares of the company’s stock valued at $1,372,000 after purchasing an additional 368 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in Encompass Health by 3.9% in the second quarter. Sequoia Financial Advisors LLC now owns 5,961 shares of the company’s stock worth $603,000 after buying an additional 225 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in Encompass Health in the second quarter worth about $112,000. Finally, Allworth Financial LP lifted its stake in shares of Encompass Health by 23.8% in the second quarter. Allworth Financial LP now owns 1,239 shares of the company’s stock worth $125,000 after buying an additional 238 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

About Encompass Health

Encompass Health Corporation (NYSE:EHC) is a provider of post-acute healthcare services in the United States. The company operates inpatient rehabilitation hospitals that care for patients recovering from illness, injury, surgery or other medical conditions requiring intensive rehabilitation.

Its rehabilitation programs commonly serve patients recovering from strokes, brain and spinal cord injuries, neurological disorders, cardiac and pulmonary conditions, hip fractures, amputations and other orthopedic conditions.